43 FY 2013 Drug GMP Warning Letters Hit Data Integrity, Training and More
This article was originally published in The Gold Sheet
Executive Summary
FDA’s 43 fiscal year 2013 drug GMP warning letters highlighted problems related to data integrity, inadequate testing of raw materials and inadequate employee training. These trends were associated with increases in warning letters to manufacturers in India and to U.S.-based compounding pharmacies.
You may also be interested in...
Key Senator Hinges Support For Cheap Drug Imports On Surprise Inspections
More unannounced inspections abroad would warm Senate Finance Committee chairman to President Trump's drug importation plan.
Contamination and Raw Material Testing Issues Raised in FDA Warning Letters
FDA investigators are continuing to find contamination problems and inadequate testing, according to 20 warning letters issued in the first half of 2013, as well as a troubling trend of repeat observations at Baxter, Hospira and Apotex. Observers say to expect more sterility concerns in future warning letters, particularly involving mold, as FDA ramps up GMP enforcement at compounding pharmacies.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”